Suppliers and packagers for generic pharmaceutical drug: colestipol hydrochloride

Executive summary: Colestipol hydrochloride is a generic, bile-acid sequestrant supplied primarily through multiple US labelers and several API and finished-dose manufacturers. The active ingredient is sourced from standard chemical/API supply chains, while finished products come from US generics manufacturers and distributors. Because the drug is off-patent and widely marketed, supplier risk is driven by current FDA-approved product availability, manufacturing site compliance, and substitute-basket dynamics (cholestyramine, colesevelam) rather than exclusivity constraints.

Who supplies colestipol hydrochloride tablets and granules in the US?

Most colestipol hydrochloride in the US market is supplied as an approved generic through different labelers holding an ANDA and listed in the FDA’s Orange Book. Suppliers typically include:

• Finished-dose generic manufacturers (ANDA holders) for tablets and/or granules
• Contract manufacturers producing under labeler brands
• Wholesalers and specialty distributors moving inventory to pharmacies and health systems
• API suppliers providing colestipol hydrochloride to formulation sites

Key point: In a generic bile-acid sequestrant market, the “supplier” most relevant to procurement is the current ANDA labeler(s) that hold the marketed product and their manufacturing sites, because that determines supply continuity, recalls, and availability.

What dosage forms are commonly supplied?

Colestipol hydrochloride products are generally marketed in:

• Tablets
• Granules / powder for oral suspension

Procurement decisions should be dosage-form specific because shelf-life, packaging, and manufacturing lines differ.

What are the typical supply channels?

• Direct from ANDA labelers to wholesalers
• Through GPO and 340B channels for institutional distribution
• Through multiple wholesalers that can carry different product NDCs (labeler-specific)

Which API suppliers make colestipol hydrochloride bulk active pharmaceutical ingredient?

API supply is handled through chemical manufacturing chains feeding finished-dose generics. In practice, API procurement is usually done by:

• ANDA manufacturers sourcing colestipol API for formulation
• Contract API and chemical suppliers providing colestipol hydrochloride bulk material to multiple downstream customers

Procurement reality: For this product, the highest-value diligence is not “single-source” mapping of every chemical supplier, but verification of:

• The API starting material traceability and change control
• The manufacturer’s GMP compliance history at the site level
• Whether the downstream ANDA manufacturer has multiple validated supply slots for API

What is the Orange Book status of colestipol hydrochloride products?

Colestipol hydrochloride is widely distributed as a generic medicine, and Orange Book listings typically show:

• ANDA approvals for multiple generic labelers
• Expired or not meaningfully constraining patent estates for the basic active ingredient and standard formulations

Key point for supplier selection: Orange Book status is used to map which ANDA holders can legally manufacture and market the drug, and to track the legal basis for marketing each NDC.

How many ANDA holders typically list colestipol hydrochloride?

The market commonly includes multiple ANDA holders over time, but the exact count changes with:

• NDC retirements
• Discontinuations
• Recalls and reinstatements
• Labeler substitutions

Supplier continuity should be validated against current NDC availability, not historical breadth.

How do supplier availability and shortages affect colestipol hydrochloride procurement?

In generic bile-acid sequestrants, availability shifts often come from:

• Finished-dose manufacturing line constraints
• Packaging component sourcing issues
• Batch failures tied to dissolution/assay specs for granular products
• Regulatory actions involving manufacturing sites or distribution lots

Operational implication: The supplier risk is most often tied to one or two active labelers that hold a large share of a specific dosage form or NDC family at any given time.

What alternative suppliers reduce substitution risk?

Procurement teams usually mitigate risk by cross-checking:

• Multiple NDCs for tablets and granules
• Backup suppliers for each dosage form
• Substitution options under therapeutic category (see below)

How does colestipol hydrochloride compare with cholestyramine and colesevelam for supply and contracting?

Colestipol hydrochloride competes in the bile-acid sequestrant class with:

• Cholestyramine (resin powder)
• Colesevelam (tablet)

Supplier and contracting dynamics:

• Colestipol’s market is often smaller than the broader sequestrant basket, which can concentrate supply in fewer active labelers.
• If colestipol inventory tightens, contracts and substitutions often shift to the closest therapeutically acceptable alternative, depending on payer coverage policies and formulary rules.

Procurement impact: When colestipol supply compresses, buyers often renegotiate or adjust fill strategy within the class rather than seeking a new API source.

What companies are the main suppliers of colestipol hydrochloride?

Without a current, product-specific Orange Book and NDC crosswalk in this session, listing named companies risks producing an incomplete or stale supplier roster.

Actionable supplier approach (what procurement should do when mapping vendors):

1. Pull all current FDA Orange Book listings for the exact dosage form and strength.
2. Identify each ANDA holder (labeler) and the associated manufacturing sites.
3. Map distributor custody (wholesalers) by the NDCs actually in pharmacy channels.
4. Build redundancy by stocking at least two suppliers per dosage form.

What are typical manufacturing and IP barriers for new colestipol entrants?

Because colestipol is generic, the main entry barriers are regulatory and operational:

• ANDA compliance (bioequivalence where applicable and chemistry controls)
• CMC readiness for tablets vs granules
• GMP manufacturing site capability
• Quality system maturity and batch release testing reliability

What CMC specs matter most for supplier qualification?

For bile-acid sequestrants, supplier qualification commonly focuses on:

• Particle size and dissolution performance (granules)
• Assay and impurities
• Uniformity of dosage units (tablets)
• Stability under packaging conditions
• Scale-up consistency between batches

Key Takeaways

• Colestipol hydrochloride is a generic, bile-acid sequestrant supplied by multiple ANDA labelers with separate manufacturing lines for tablets and granules.
• Procurement supplier risk is driven by current NDC availability, manufacturing site continuity, and batch release reliability, not IP exclusivity.
• The practical supplier mapping workflow is Orange Book listing to ANDA holder to manufacturing site to current NDC distribution.
• Shortages and substitution decisions generally route through the class alternatives (cholestyramine, colesevelam) and within-dosage-form NDC diversification.

FAQs

1. Which NDCs for colestipol hydrochloride are currently available?
   Determine using the Orange Book NDC listings for tablets and granules tied to the specific strength.

2. Can a pharmacy substitute colestipol hydrochloride with cholestyramine or colesevelam?
   Substitution depends on formulary policy and clinical guidance, not patent status.

3. Are there patent restrictions that limit who can market colestipol hydrochloride?
   For this product, marketing is generally governed by ANDA eligibility rather than active patent barriers.

4. What dosage form is most sensitive to supply disruption, tablets or granules?
   Granules can be more exposed to packaging and particle/dissolution performance constraints, but the exact vulnerability is labeler-specific.

5. How should procurement qualify a new colestipol hydrochloride supplier?
   Use site-level GMP history, batch release data, stability and CMC comparability, and ensure multiple approved NDC options exist for redundancy.

References (APA)

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/